Merck & Co Inc. (MRK) News Headlines

▮ More

Date

Headline

6/30/2020 8:58:10 AM FDA OKs Merck's Keytruda As First-line Treatment For Metastatic Colorectal Cancer

6/30/2020 2:28:49 AM AstraZeneca : Selumetinib Granted Orphan Drug Designation In Japan For Neurofibromatosis Type 1

6/29/2020 1:28:17 AM Novo Nordisk Announces Approval Of Rybelsus In Japan For Treatment Of Type 2 Diabetes

6/22/2020 7:20:06 AM Merck: KEYTRUDA Approved For New Indication In China - Quick Facts

6/22/2020 6:57:01 AM Merck Says V114 Vaccine Meets Safety Objectives In Initial Phase 3 Studies In Adults

6/22/2020 6:54:54 AM Merck's KEYTRUDA Approved By NMPA In China

6/17/2020 7:42:17 AM Merck: FDA Approves Second Biomarker-Based Indication For KEYTRUDA

6/17/2020 7:03:40 AM Merck Prices $4.5 Bln Public Debt Offering Of Senior Unsecured Notes - Quick Facts

6/17/2020 6:54:12 AM Merck Prices $4.5 Bln Public Offering Of Four Series Of Senior Unsecured Notes

6/17/2020 6:50:26 AM Merck: FDA Approves KEYTRUDA For Adult And Pediatric Patients With Unresectable Or Metastatic TMB-H

6/5/2020 6:46:47 AM FDA OKs Merck's Recarbrio For Hospital And Ventilator Associated Bacterial Pneumonia

6/4/2020 11:32:57 PM CYCN Awaits Sickle Cell Disease Data, TTPH Finalizes Its Suitor, ADMS Faces FDA In Feb

6/4/2020 12:37:03 AM List Of 'Operation Warp Speed' Finalists, SAVA To Reassess AD Study Results; KZR Jumps On MISSION

6/1/2020 2:28:27 AM AstraZeneca: Lynparza Recommended For Marketing Authorisation In EU

5/30/2020 6:41:10 AM The Week That Was: MRK Enters COVID Space, GSK's 1Bln Dose Target, Roche, GILD Team Up For REMDACTA

5/26/2020 11:30:00 PM ARGX Soars On ADAPT Trial Data, MRK's Deals & Collaborations To Fight COVID-19, ALNY ON Watch

5/26/2020 9:37:34 AM Merck Inks Deals, Joins Coronavirus Vaccine Race

5/26/2020 8:34:52 AM Merck, Ridgeback Bio Collaborate To Develop Novel Antiviral Candidate EIDD-2801

5/26/2020 8:23:05 AM Merck To Buy Privately-held Themis - Quick Facts

5/26/2020 8:18:53 AM Merck And Ridgeback Bio Enter Collaboration Agreement To Develop Novel Antiviral Candidate, EIDD-2801